

July 30, 2026

Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 [IFRS]

Company name: Konica Minolta, Inc.
 Stock exchange listings: Tokyo (Prime Market)
 Securities code number: 4902
 URL: <https://konicaminolta.com>
 Representative: Toshimitsu Taiko
 Contact: President and CEO, Representative Executive Officer
 Koichiro Hattori
 General Manager, Corporate Accounting Division
 Telephone number: (81) 3-6250-2111
 Scheduled date for dividends payment: –
 Availability of supplementary information for the quarterly financial results: Yes
 Organization of briefing on the quarterly financial results: Yes (for institutional investors)

(Amounts less than one million yen are rounded down to the nearest million yen.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated results of operations

(Percentage figures represent changes from the same period of the previous fiscal year.)

Three months ended	Revenue		Business contribution profit		Operating profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	258,517	2.9	11,566	25.8	9,620	–4.4
June 30, 2025	251,204	–8.2	9,195	411.0	10,062	–

Three months ended	Profit before tax		Profit for the period		Profit attributable to owners of the Company	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	7,608	–14.4	7,813	2.7	7,780	6.8
June 30, 2025	8,891	–	7,606	–	7,283	–

Three months ended	Basic earnings per share	Diluted earnings per share
	Yen	Yen
June 30, 2026	15.74	15.68
June 30, 2025	14.74	14.70

(Notes)

1. "Business contribution profit" is calculated by deducting the cost of sales and selling, general and administrative expenses from revenue.
2. Total comprehensive income for the three months ended June 30, 2026 and 2025, was 17,893 million yen (an increase of 313.4% year-on-year) and 4,328 million yen (a decrease of 79.7% year-on-year), respectively.
3. Basic earnings per share and diluted earnings per share are calculated based on the profit attributable to owners of Konica Minolta, Inc. (the "Company").
4. The Precision Medicine Business is classified as a discontinued operation from the three months ended December 31, 2024. As a result, revenue, business contribution profit, operating profit, and profit before tax represent the amount of continuing operations excluding the discontinued operation. Profit for the period and profit attributable to owners of the Company represent the sum of continuing operations and the discontinued operation.

(2) Consolidated financial position

As of	Total assets	Total equity	Equity attributable to owners of the Company	Equity ratio attributable to owners of the Company
	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2026	1,229,912	563,398	550,786	44.8
March 31, 2026	1,234,909	548,971	536,505	43.4

2. Dividends per share

	End of the three-month period	End of the six- month period	End of the nine-month period	End of the year	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	–	5.00	–	7.00	12.00
Fiscal year ending March 31, 2027	–				
Fiscal year ending March 31, 2027 (forecast)		9.00	–	9.00	18.00

(Note) Changes from the latest dividend forecasts: None

3. Consolidated forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentage figures represent changes from the previous fiscal year.)

Fiscal year ending	Revenue		Business contribution profit		Operating profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2027	1,105,000	1.6	56,000	5.3	50,000	0.3

Fiscal year ending	Profit attributable to owners of the Company		Basic earnings per share
	Millions of yen	%	Yen
March 31, 2027	28,500	-5.8	57.57

(Note) Changes from the latest consolidated forecasts: None

■ Notes

- (1) Significant changes in the scope of consolidation for the three months ended June 30, 2026:
None
- (2) Changes in accounting policies or changes in accounting estimates
- | | |
|---|------|
| a. Changes in accounting policies required by International Financial Reporting Standards (IFRS): | None |
| b. Changes in accounting policies other than the above a.: | None |
| c. Changes in accounting estimates: | None |
- (3) Number of issued and outstanding shares (common stock)
- | | |
|--|--------------------|
| a. Number of issued and outstanding shares (including treasury shares) | |
| As of June 30, 2026: | 502,664,337 shares |
| As of March 31, 2026: | 502,664,337 shares |
| b. Number of treasury shares | |
| As of June 30, 2026: | 7,899,641 shares |
| As of March 31, 2026: | 8,480,644 shares |
| c. Average number of issued and outstanding shares during the period | |
| The three months ended June 30, 2026: | 494,334,247 shares |
| The three months ended June 30, 2025: | 494,239,924 shares |

(Note) The Company has established the Board Incentive Plan. The shares owned by the trust account relating to this trust are accounted for as treasury shares (2,060,878 shares as of June 30, 2026, and 2,631,462 shares as of March 31, 2026).

- Review procedures performed by certified public accountants or an audit firm for the attached quarterly consolidated financial statements: None
- Explanation concerning the appropriate use of the forecasts for results of operations and other special matters

Note on the forecasts for the consolidated financial results

The forecasts for results of operations in this report are based on information currently available to the Company and its subsidiaries (the “Group”) and certain assumptions determined to be reasonable, and are not intended to assure any achievement of the Group’s operations. Actual results may differ significantly from the forecasts due to various factors. For further details of the assumptions that form the basis of the forecasts and other related matters when referring to the forecasts, refer to “1. OVERVIEW OF FINANCIAL RESULTS, (3) Explanation Regarding the Forecasts for the Consolidated Financial Results” in the attached Supplementary Information on page 12.

Supplementary information for the quarterly financial results and briefing on the quarterly financial results

The Company will hold a briefing on the quarterly financial results for institutional investors on Thursday, July 30, 2026. The proceedings and details of the briefing, along with the supplementary information on the quarterly financial results to be presented at the briefing, will be posted on the website of the Group soon after the briefing.

Supplementary Information

Table of Contents

1. OVERVIEW OF FINANCIAL RESULTS	6
(1) Overview of Consolidated Operating Results for the three months ended June 30, 2026	6
(2) Overview of Consolidated Financial Position for the three months ended June 30, 2026	10
(3) Explanation Regarding the Forecasts for the Consolidated Financial Results	12
2. QUARTERLY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES	13
(1) Quarterly Condensed Consolidated Statements of Financial Position	13
(2) Quarterly Condensed Consolidated Statements of Profit or Loss	15
(3) Quarterly Condensed Consolidated Statements of Comprehensive Income	16
(4) Quarterly Condensed Consolidated Statements of Changes in Equity	17
(5) Quarterly Condensed Consolidated Statements of Cash Flows	19
(6) Notes to the Quarterly Condensed Consolidated Financial Statements	21
[Notes Regarding Going Concern Assumptions]	21
[Other Income]	21
[Other Expenses]	21
[Segment Information]	22
[Cash and Cash equivalents]	25
[Discontinued Operation]	25

1. OVERVIEW OF FINANCIAL RESULTS

(1) Overview of Consolidated Operating Results for the three months ended June 30, 2026

a. Overview

	Three months ended June 30, 2025	Three months ended June 30, 2026	Increase (Decrease)	
	Billions of yen	Billions of yen	Billions of yen	%
Revenue (Note2)	251.2	258.5	7.3	2.9
Gross profit (Note2)	110.2	124.0	13.7	12.5
Business contribution profit (loss) (Note1) (Note2)	9.1	11.5	2.3	25.8
Operating profit (loss) (Note2)	10.0	9.6	(0.4)	-4.4
Profit (loss) before tax (Note2)	8.8	7.6	(1.2)	-14.4
Profit (loss) attributable to owners of the Company (Note2)	7.2	7.7	0.4	6.8
	Yen	Yen	Yen	%
Basic earnings (loss) per share (Note2)	14.74	15.74	1.00	6.8
	Billions of yen	Billions of yen	Billions of yen	%
Capital expenditures	25.0	8.8	(16.1)	-64.6
Depreciation and amortization expenses	13.9	15.6	1.7	12.6
Research and development expenses (Note2)	13.1	13.5	0.3	3.0
	Billions of yen	Billions of yen	Billions of yen	%
Free cash flows	(18.8)	17.4	36.3	—
	Number	Number	Number	%
Number of employees in the Group	34,779	34,133	(646)	-1.9
	Yen	Yen	Yen	%
Foreign exchange rates				
U.S. dollar	144.59	159.49	14.90	10.3
Euro	163.80	185.39	21.59	13.2

(Notes)

1. "Business contribution profit" is calculated by deducting the cost of sales and selling, general and administrative expenses from revenue.
2. The Precision Medicine Business is classified as a discontinued operation from the three months ended December 31, 2024. As a result, revenue, gross profit, business contribution profit, operating profit or loss, profit or loss before tax, and research and development expense represent the amount of continuing operations excluding the discontinued operation. Profit or loss attributable to owners of the Company and basic earnings or loss per share represent the sum of continuing operations and the discontinued operation.

b. Overview by Segment

		Three months ended June 30, 2025	Three months ended June 30, 2026	Increase (Decrease)	
		Billions of yen	Billions of yen	Billions of yen	%
Digital Workplace Business	Revenue	139.6	149.1	9.4	6.8
	Business contribution profit	7.0	8.9	1.8	25.7
	Operating profit	6.7	7.7	1.0	14.9
Professional Print Business	Revenue	64.2	58.1	(6.1)	-9.6
	Business contribution profit	1.4	4.3	2.9	206.2
	Operating profit	0.4	4.0	3.5	795.7
Industry Business	Revenue	28.8	31.7	2.9	10.4
	Business contribution profit	3.9	5.2	1.3	33.6
	Operating profit	4.0	5.2	1.2	31.2
Imaging Solutions Business	Revenue	18.3	19.3	0.9	5.4
	Business contribution profit	(0.5)	(1.2)	(0.6)	—
	Operating profit	1.4	(1.6)	(3.1)	—
Subtotal	Revenue	251.0	258.3	7.2	2.9
	Business contribution profit	11.8	17.2	5.4	45.5
	Operating profit	12.6	15.3	2.6	21.1
Others and Adjustments (Note 2)	Revenue	0.1	0.1	0	15.1
	Business contribution profit	(2.6)	(5.7)	(3.0)	—
	Operating profit	(2.6)	(5.7)	(3.1)	—
Amount Reported in the Quarterly Condensed Consolidated Statements of Profit or Loss	Revenue	251.2	258.5	7.3	2.9
	Business contribution profit	9.1	11.5	2.3	25.8
	Operating profit	10.0	9.6	(0.4)	-4.4

(Notes)

1. “Revenue” refers to revenue from external customers.
2. “Revenue” refers to revenue from external customers in “Others” in “2. QUARTERLY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES, (6) Notes to the Quarterly Condensed Consolidated Financial Statements, [Segment Information].” “Operating profit” is the total of “Others” and “Adjustments” of segment profit (loss) within the same table.
3. The Precision Medicine Business is classified as a discontinued operation from the three months ended December 31, 2024. Accordingly, the amounts presented represent continuing operations excluding the discontinued operation.
4. Effective from the current fiscal year, certain businesses previously included in the “Imaging Solutions Business” have been reclassified, including video solution services to the “Digital Workplace Business” and gas monitoring solutions to the “Industry Business,” to reflect changes in the actual management structure. Accordingly, figures for the previous fiscal year have also been disclosed based on figures after reflecting these changes.

Under the “Corporate Plan 2026–2028,” the Company has positioned the three-year period as a phase to build a foundation for long-term growth. The current fiscal year ending March 31, 2027, which is the first

year, the Company focused on profit growth centered on the Industry Business and Professional Print Business, strengthening of financial structure, and commercialization of growth seeds.

During the three months ended June 30, 2026 (the "current period"), the Group's consolidated revenue amounted to 258.5 billion yen (an increase of 2.9% year-on-year). This is due to the contribution of increase in revenue year on year of the Digital Workplace Business, the Industry Business, and the Imaging Solutions Business supported by the impact of yen depreciation in exchange rates.

Gross profit amounted to 124.0 billion yen (an increase of 12.5% year-on-year). Gross profit increased in the Digital Workplace Business, the Professional Print Business, and the Industry Business. This included a 7.4 billion yen refunds related to U.S. tariff expenses recorded in the previous fiscal year.

Selling, general and administrative expenses amounted to 112.4 billion yen (an increase of 11.3% year-on-year), reflecting the impact of foreign exchange rates and the absence of one-time factors that reduced expenses recorded in the same period of the previous fiscal year.

As a result, business contribution profit was 11.5 billion yen (an increase of 25.8% year-on-year).

Operating profit was 9.6 billion yen (a decrease of 4.4% year-on-year). Business structure improvement expenses of 1.1 billion yen related to the overseas Digital Workplace Business and the Professional Print Business (compared to 0.1 billion yen in the same period of the previous fiscal year) were recorded as other expenses.

The summary of revenue, business contribution profit, and operating profit of each business is as follows:

i. Digital Workplace Business

Revenue of the Digital Workplace Business was 149.1 billion yen (an increase of 6.8% year-on-year).

Revenue of the office unit increased year-on-year due to the effect of yen depreciation in exchange rates. Excluding foreign exchange effects, the hardware (sales of equipment) revenue decreased in reaction to the large contracts of the same period of the previous fiscal year, and the non-hardware (consumables, services, and others) revenue decreased due to a decline in the amount of equipment in operation in the market. Regionally, the hardware revenue decreased mainly in the United States and China, and the non-hardware revenue decreased mainly in Europe and the United States.

In the DW-DX unit, which mainly offers services, such as IT services, revenue increased year-on-year. In addition to the effect of yen depreciation, the services to manage business content and operation processes progressed in Europe, the United States, and Japan, and in-house-developed AI SaaS business, such as AI-based learning support services and others, grew in Japan.

The business contribution profit of the Digital Workplace Business was 8.9 billion yen (an increase of 25.7% year-on-year). In the office unit, gross profit increased benefiting from the aforementioned U.S. tariff refunds.

Operating profit was 7.7 billion yen (an increase of 14.9% year-on-year). As part of other expenses, the aforementioned business structure improvement expenses were recorded.

ii. Professional Print Business

Revenue of the Professional Print Business was 58.1 billion yen (a decrease of 9.6% year-on-year).

In the production print unit, revenue decreased. This was affected by a lack of revenue due to the transfer of shares of Konica Minolta Marketing Services Holding Company Limited, which was implemented in the same period of the previous fiscal year as part of business selection and concentration. Excluding this impact, however, revenue increased, supported by the positive effect of yen depreciation. Hardware revenue increased due to the effect of yen depreciation in exchange rates. Excluding foreign exchange effects, revenue decreased in Europe, the United States, and China, but grew in India. Non-hardware revenue increased. Excluding foreign exchange effects, revenue decreased in Europe and China, but grew in the United States and India.

In the industrial print unit, revenue increased year-on-year, benefiting from foreign exchange. Revenue of hardware and non-hardware increased due to the increased sales volume of label press despite the decreased sales volumes of inkjet press and embellishment press.

The business contribution profit of the Professional Print Business was 4.3 billion yen (an increase of 206.2% year-on-year). Profit increased benefiting from the aforementioned U.S. tariffs refunds.

Operating profit was 4.0 billion yen (an increase of 795.7% year-on-year). Profit increased benefiting from a lack of the loss on sales of subsidiaries associated with the transfer of shares.

iii. Industry Business

Revenue of the Industry Business was 31.7 billion yen (an increase of 10.4% year-on-year).

Revenue in the sensing unit increased year-on-year. Sales of light source color measurement instruments increased due to an increased capital investments in displays by major customers. Sales of measurement instruments applying hyperspectral imaging technology increased due to steady orders. Sales of testing equipment for automotive visual inspections remained steady.

In the performance materials unit, revenue decreased year-on-year. Although the demand for films remained steady, supply was constrained in the current period because production capacity limitations in the previous fiscal year resulted in insufficient inventory levels.

In the inkjet (IJ) components unit, revenue increased year-on-year. Sales performed well in the sign graphics market, reflecting contributions from new products launched in the previous fiscal year. In addition, business other than IJ head and ink performed well.

In the optical components unit, revenue increased year-on-year. Interchangeable lenses for camera performed well driven by the increasing demand. Sales of optical components for semiconductor inspection equipment, on which the Company focuses, remained steady supported by the increasing demand due to chiplet integration and by the expansion of production capacity to meet the demand.

The business contribution profit of the Industry Business amounted to 5.2 billion yen (a 33.6% increase year-on-year). This was supported by the growth in gross profit due to higher sales centered on sensing unit.

Operating profit was 5.2 billion yen (an increase of 31.2% year-on-year).

iv. Imaging Solutions Business

The Imaging Solutions Business recorded a revenue of 19.3 billion yen (an increase of 5.4% year-on-year).

The healthcare unit saw an increase in revenue year-on-year due to the effect of yen depreciation. The sales of DR (Digital Radiography) grew due to the increased sales to other companies' brand and sales in India. The unit saw a sales growth in healthcare IT in the United States. Meanwhile, sales of purchased products in Japan decreased.

The visual solutions unit saw an increase in revenue year-on-year. Sales of LED solutions progressed steadily.

The imaging IoT solutions unit implemented portfolio optimization and transferred part of its business to other businesses.

The business contribution loss was 1.2 billion yen (the loss was 0.5 billion yen in the same period of the previous fiscal year). The business contribution loss increased due to the spike in the price of silver, a raw material, in the healthcare unit and the absence of one-time factors that reduced expenses recorded in the same period of the previous fiscal year.

Operating loss was 1.6 billion yen (the profit was 1.4 billion yen in the same period of the previous fiscal year). This was due to the absence of gain on sales of subsidiaries associated with the transfer of equity capital of MOBOTIX AG recorded in the same period of the previous fiscal year.

The Group's profit before tax for the current period was 7.6 billion yen (a decrease of 14.4% year-on-year). Financial balance has deteriorated by 0.8 billion yen mainly due to the absence of gains on the acquisition of real estate trust beneficiary interests recorded in the same period of the previous fiscal year.

The profit from continuing operations was 4.8 billion yen (an increase of 5.3% year-on-year). In addition to the improved profitability in U.S. subsidiary benefiting from the aforementioned refunds related to tariff expenses, tax expense decreased by utilizing loss carryforwards.

The profit from discontinued operations was 2.9 billion yen (a decrease of 1.2% year-on-year). A profit of 2.9 billion yen, which was a gain from the sale of the shares of Tempus AI, Inc ("Tempus") received as consideration for the transfer of shares of Ambry Genetics Corporation ("Ambry Genetics"), is included. The Company has completed the sale of all shares of Tempus AI, Inc it held.

The profit attributable to owners of the Company was 7.7 billion yen (an increase of 6.8% year-on-year).

(2) Overview of Consolidated Financial Position for the three months ended June 30, 2026

a. Analysis of Consolidated Financial Position

	As of March 31, 2026	As of June 30, 2026	Increase (Decrease)
	Billions of yen	Billions of yen	Billions of yen
Total assets	1,234.9	1,229.9	(4.9)
Total liabilities	685.9	666.5	(19.4)
Total equity	548.9	563.3	14.4
Equity attributable to owners of the Company	536.5	550.7	14.2
	%	%	%
Equity ratio attributable to owners of the Company	43.4	44.8	1.4

Total assets as of June 30, 2026, were 1,229.9 billion yen, a decrease of 4.9 billion yen (0.4%) from March 31, 2026. This is primarily attributed to a decrease of 19.9 billion yen in trade and other receivables; a decrease of 11.3 billion yen in other financial assets; an increase of 10.9 billion yen in inventories; an increase of 6.2 billion yen in cash and cash equivalents; and an increase of 6.1 billion yen in other current assets.

Total liabilities as of June 30, 2026, were 666.5 billion yen, a decrease of 19.4 billion yen (2.8%) from March 31, 2026. This is primarily attributed to a decrease of 10.3 billion yen in trade and other payables, and a decrease of 5.1 billion yen in other current liabilities.

Total equity as of June 30, 2026, was 563.3 billion yen, an increase of 14.4 billion yen (2.6%) from March 31, 2026.

Equity attributable to owners of the Company was 550.7 billion yen as of June 30, 2026, an increase of 14.2 billion yen (2.7%) from March 31, 2026. This is primarily attributed to an increase of 9.8 billion yen in other components of equity (primarily exchange differences on translation of foreign operations) and an increase of 7.7 billion yen in profit attributable to owners of the Company.

As a result of the above, the equity ratio attributable to owners of the Company increased by 1.4 percentage points to 44.8%.

b. Analysis of Consolidated Cash Flows

	Three months ended June 30, 2025	Three months ended June 30, 2026	Increase (Decrease)
	Billions of yen	Billions of yen	Billions of yen
Cash flows from operating activities	(11.5)	11.6	23.1
Cash flows from investing activities	(7.3)	5.8	13.1
Total (free cash flows)	(18.8)	17.4	36.3
Cash flows from financing activities	13.0	(12.7)	(25.7)

For the three months ended June 30, 2026, net cash provided by operating activities was 11.6 billion yen and net cash provided by investing activities totaled 5.8 billion yen. As a result, free cash flows (the sum of cash flows from operating activities and investing activities) were an inflow of 17.4 billion yen for the current period.

Net cash used in financing activities was 12.7 billion yen.

In addition, cash and cash equivalents as of June 30, 2026, increased by 6.2 billion yen from March 31, 2026, to 116.9 billion yen, mainly reflecting the effect of exchange rate fluctuations on cash and cash equivalents.

Cash flows from operating activities

Net cash provided by operating activities was 11.6 billion yen. On top of the profit before tax of 7.6 billion yen and profit before tax from discontinued operation of 2.9 billion yen, this is attributable to net effects of cash inflows mainly due to a decrease in trade and other receivables of 25.3 billion yen, and depreciation and amortization expenses of 15.6 billion yen, and cash outflows mainly due to a decrease in trade and other payables of 11.8 billion yen and an increase in inventory of 8.1 billion yen.

In addition, cash flows from operating activities include the impact of refunds related to U.S. tariff expenses recorded in the previous fiscal year.

Cash flows from investing activities

Net cash provided by investing activities was 5.8 billion yen, mainly due to the proceeds from the sales of investment securities of 16.1 billion yen, the purchase of the property, plant and equipment of 6.9 billion yen and the purchase of intangible assets of 3.2 billion yen.

In addition, proceeds from sales of investment securities include proceeds from the sale of the Tempus shares received as consideration for the transfer of shares of Ambry Genetics.

As a result, free cash flows (the sum of cash flows from operating activities and investing activities) were an inflow of 17.4 billion yen (an outflow of 18.8 billion yen for the same period in the previous fiscal year).

Cash flows from financing activities

Net cash used in financing activities was 12.7 billion yen (net cash inflow of 13.0 billion yen for the same period in the previous fiscal year), reflecting cash outflows of a net decrease in short-term loans payable of 5.7 billion yen, repayments of lease liabilities of 5.2 billion yen, cash dividends paid of 3.2 billion yen, and cash inflows of bonds issuance and long-term loans payable of 2.2 billion yen.

(3) Explanation Regarding the Forecasts for the Consolidated Financial Results

The Company has decided to leave its full-year forecasts unchanged from those announced on May 14, 2026, considering the progress made during the three months period of the current three months ended June 30.

The exchange rates after the second quarter, which are the assumptions for the forecast, have also unchanged from the yen against the U.S. dollar to 150 yen and 180 yen to the euro.

* The above forecasts for the results of operations are based on suppositions, outlooks, and plans as of the release date of this report and as such, they involve risks and uncertainties. Actual results may differ significantly from these forecasts due to various important factors, such as changes in economic conditions, market trends, and currency exchange rates.

Amounts in “1. OVERVIEW OF FINANCIAL RESULTS” are rounded down to the nearest stated unit.

2. QUARTERLY CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES

(1) Quarterly Condensed Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	110,762	116,986
Trade and other receivables	316,640	296,685
Inventories	210,467	221,450
Income tax receivables	3,562	3,647
Other financial assets	14,122	1,464
Other current assets	37,461	43,620
Total current assets	693,017	683,856
Non-current assets		
Property, plant and equipment	259,533	259,950
Goodwill and intangible assets	182,775	184,092
Investments accounted for using the equity method	1,086	1,071
Other financial assets	23,601	24,933
Deferred tax assets	28,235	28,959
Other non-current assets	46,659	47,047
Total non-current assets	541,892	546,055
Total assets	1,234,909	1,229,912

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Trade and other payables	172,737	162,383
Bonds and borrowings	113,670	117,353
Lease liabilities	19,962	18,384
Income tax payables	6,481	7,467
Provisions	14,114	12,428
Other financial liabilities	2,088	39
Other current liabilities	65,540	60,363
Total current liabilities	394,596	378,420
Non-current liabilities		
Bonds and borrowings	215,969	211,636
Lease liabilities	48,709	49,647
Retirement benefit liabilities	15,688	15,494
Provisions	4,039	3,912
Other financial liabilities	873	1,051
Deferred tax liabilities	2,957	3,204
Other non-current liabilities	3,104	3,146
Total non-current liabilities	291,342	288,093
Total liabilities	685,938	666,513
Equity		
Share capital	37,519	37,519
Share premium	203,664	203,474
Retained earnings	145,680	150,058
Treasury shares	(8,894)	(8,607)
Share acquisition rights	158	150
Other components of equity	158,377	168,191
Equity attributable to owners of the Company	536,505	550,786
Non-controlling interests	12,466	12,611
Total equity	548,971	563,398
Total liabilities and equity	1,234,909	1,229,912

(2) Quarterly Condensed Consolidated Statements of Profit or Loss

Three months ended June 30, 2025 and 2026

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Continuing Operations		
Revenue	251,204	258,517
Cost of sales	140,950	134,474
Gross profit	110,253	124,042
Other income	3,866	659
Selling, general and administrative expenses	101,058	112,476
Other expenses	2,998	2,605
Operating profit (loss)	10,062	9,620
Finance income	1,897	1,276
Finance costs	3,071	3,260
Share of profit (loss) of investments accounted for using the equity method	2	(28)
Profit (loss) before tax	8,891	7,608
Income tax expense (income)	4,268	2,742
Profit (loss) from continuing operations	4,622	4,865
Discontinued Operation		
Profit (loss) from discontinued operation	2,984	2,948
Profit (loss) for the period	7,606	7,813
Profit (loss) attributable to:		
Owners of the Company	7,283	7,780
Non-controlling interests	322	33
Earnings (loss) per share	Yen	Yen
Basic	14.74	15.74
Continuing operations	8.73	9.77
Discontinued operation	6.01	5.96
Diluted	14.70	15.68
Continuing operations	8.71	9.74
Discontinued operation	5.99	5.94

(3) Quarterly Condensed Consolidated Statements of Comprehensive Income

Three months ended June 30, 2025 and 2026

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit (loss) for the period	7,606	7,813
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Remeasurements of defined benefit pension plans (net of tax)	(549)	—
Net gain (loss) on revaluation of financial assets measured at fair value (net of tax)	61	1,212
Total items that will not be reclassified to profit or loss	(488)	1,212
Items that may be subsequently reclassified to profit or loss		
Net gain (loss) on derivatives designated as cash flow hedges (net of tax)	(24)	(7)
Exchange differences on translation of foreign operations (net of tax)	(2,753)	8,854
Share of other comprehensive income of investments accounted for using the equity method (net of tax)	(11)	20
Total items that may be subsequently reclassified to profit or loss	(2,789)	8,867
Total other comprehensive income (loss)	(3,277)	10,079
Total comprehensive income (loss)	4,328	17,893
Total comprehensive income (loss) attributable to:		
Owners of the Company	4,196	17,658
Non-controlling interests	131	235

(4) Quarterly Condensed Consolidated Statements of Changes in Equity

(Millions of yen)

	Share capital	Share premium	Retained earnings	Treasury shares	Share acquisition rights	Other components of equity	Equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2025	37,519	203,899	116,401	(8,652)	188	113,798	463,154	10,924	474,079
Profit (loss) for the period	—	—	7,283	—	—	—	7,283	322	7,606
Other comprehensive income (loss)	—	—	—	—	—	(3,087)	(3,087)	(190)	(3,277)
Total comprehensive income (loss)	—	—	7,283	—	—	(3,087)	4,196	131	4,328
Acquisition and disposal of treasury shares	—	—	(7)	(299)	—	—	(306)	—	(306)
Share-based payments	—	(6)	—	—	(19)	—	(26)	—	(26)
Changes in the scope of consolidation	—	—	—	—	—	—	—	(348)	(348)
Changes in ownership interests in subsidiaries	—	(89)	—	—	—	—	(89)	(176)	(266)
Equity and other transactions with non-controlling shareholders	—	(1)	—	—	—	—	(1)	—	(1)
Transfer from other components of equity to retained earnings	—	—	(549)	—	—	549	—	—	—
Total transactions with owners	—	(97)	(557)	(299)	(19)	549	(423)	(525)	(948)
Balance as of June 30, 2025	37,519	203,801	123,128	(8,952)	169	111,261	466,927	10,531	477,459

(Millions of yen)

	Share capital	Share premium	Retained earnings	Treasury shares	Share acquisition rights	Other components of equity	Equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2026	37,519	203,664	145,680	(8,894)	158	158,377	536,505	12,466	548,971
Profit (loss) for the period	—	—	7,780	—	—	—	7,780	33	7,813
Other comprehensive income (loss)	—	—	—	—	—	9,878	9,878	201	10,079
Total comprehensive income (loss)	—	—	7,780	—	—	9,878	17,658	235	17,893
Dividends	—	—	(3,459)	—	—	—	(3,459)	(90)	(3,549)
Acquisition and disposal of treasury shares	—	—	(6)	286	—	—	279	—	279
Share-based payments	—	(190)	—	—	(7)	—	(198)	—	(198)
Equity and other transactions with non-controlling shareholders	—	0	—	—	—	—	0	—	0
Transfer from other components of equity to retained earnings	—	—	63	—	—	(63)	—	—	—
Total transactions with owners	—	(189)	(3,402)	286	(7)	(63)	(3,376)	(90)	(3,466)
Balance as of June 30, 2026	37,519	203,474	150,058	(8,607)	150	168,191	550,786	12,611	563,398

(5) Quarterly Condensed Consolidated Statements of Cash Flows

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit (loss) before tax	8,891	7,608
Profit (loss) before tax from discontinued operation	2,971	2,943
Depreciation and amortization expenses	13,902	15,655
Impairment losses and reversal of impairment losses	208	240
Share of (profit) loss of investments accounted for using the equity method	(2)	28
Interest and dividends income	(795)	(1,273)
Interest expenses	2,648	2,955
(Gain) loss on sales and disposals of property, plant and equipment, and intangible assets	(348)	330
(Increase) decrease in trade and other receivables	12,200	25,373
(Increase) decrease in inventories	(7,099)	(8,189)
Increase (decrease) in trade and other payables	(14,294)	(11,872)
Decrease due to transfer of rental assets	(1,172)	(1,086)
Increase (decrease) in retirement benefit liabilities	(22)	(1,335)
Others	(22,605)	(14,935)
Subtotal	(5,519)	16,442
Dividends received	115	183
Interest received	806	1,082
Interest paid	(3,034)	(3,242)
Income taxes (paid) refunded	(3,888)	(2,798)
Net cash provided by (used in) operating activities	(11,519)	11,666

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from investing activities		
Purchase of property, plant and equipment	(24,899)	(6,949)
Purchase of intangible assets	(2,787)	(3,222)
Proceeds from sales of property, plant and equipment, and intangible assets	1,449	499
Proceeds from sales of subsidiaries	3,096	—
Payments for sales of subsidiaries	(1,046)	—
Proceeds from sales of investment securities	16,966	16,116
Others	(85)	(631)
Net cash provided by (used in) investing activities	(7,305)	5,812
Cash flows from financing activities		
Increase (decrease) in short-term loans payable	18,877	(5,758)
Proceeds from bonds issuance and long-term loans payable	52	2,252
Redemption of bonds and repayments of long-term loans payable	(144)	(611)
Repayments of lease liabilities	(5,191)	(5,255)
Cash dividends paid	(1)	(3,257)
Payment of dividends to non-controlling shareholders	—	(90)
Payment for purchases of investments in subsidiaries with no changes in scope of consolidation	(266)	—
Others	(325)	(0)
Net cash provided by (used in) financing activities	13,001	(12,721)
Effect of exchange rate changes on cash and cash equivalents	(411)	1,466
Net increase (decrease) in cash and cash equivalents	(6,234)	6,223
Cash and cash equivalents at the beginning of the period	92,887	110,762
Cash and cash equivalents at the end of the period	86,652	116,986

(6) Notes to the Quarterly Condensed Consolidated Financial Statements

[Notes Regarding Going Concern Assumptions]

Not Applicable.

[Other Income]

Components of other income are as follows:

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Gain on sales of shares in subsidiaries	2,271	—
Others	1,595	659
Total	3,866	659

[Other Expenses]

Components of other expenses are as follows:

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Business structure improvement expenses	181	1,146
Loss on sales of shares in subsidiaries	1,034	—
Others	1,782	1,458
Total	2,998	2,605

[Segment Information]

(a) Reportable segments

Operating segments of the Group are its components for which separate financial data is available and that are examined on a regular basis for the purpose of enabling the Group's management to decide on the allocation of resources and evaluate the results of operations. The Group has established business units by product and service category and formulates comprehensive strategies and conducts business activities in Japan and overseas for the products and services of each business unit.

The Group comprises operating segments organized by product and service category based on each business unit, and based on the operating segments, the Group established four reportable segments as the "Digital Workplace Business," "Professional Print Business," "Industry Business," and "Imaging Solutions Business" while taking into account the primary usage of products of the respective businesses in the markets and their similarities.

Effective from the current fiscal year, certain businesses previously included in the "Imaging Solutions Business" have been reclassified, including video solution services to the "Digital Workplace Business" and gas monitoring solutions to the "Industry Business," to reflect changes in the actual management structure. Accordingly, figures for the previous fiscal year have also been disclosed based on figures after reflecting these changes.

Businesses of each reportable segment are described as follows:

		Business content
Business Technologies Business (Note)	Digital Workplace Business	<u>Office</u> Development, manufacture, and sales of MFPs and related consumables; provision of related services and solutions
		<u>DW-DX</u> Provision of IT services and solutions
	Professional Print Business	<u>Production Print</u> Development, manufacture, and sales of digital printing systems and related consumables for the commercial printing market; provision of various printing services and solutions
		<u>Industrial Print</u> Development, manufacture, and sales of digital printing systems and related consumables for the industrial printing market
Industry Business		<u>Sensing</u> Development, manufacture, and sales of measuring instruments and others; provision of related solutions and services
		<u>Performance Materials</u> Development, manufacture, and sales of functional films for displays and others
		<u>Inkjet (IJ) Components</u> Development, manufacture, and sales of industrial inkjet printheads and others
		<u>Optical Components</u> Development, manufacture, and sales of lenses for industrial and professional use and others
Imaging Solutions Business		<u>Healthcare</u> Development, manufacture, and sales of diagnostic imaging systems for medical use; provision of related services; provision of digitalization, networking, diagnostic services, and solutions in medical field
		<u>Imaging-IoT Solutions</u> Provision of solutions and services centered on network cameras
		<u>Visual Solutions</u> Development, manufacture, and sales of visual-related equipment; provision of related solutions and services
		<u>QOL Solutions</u> Development, sales, and consulting of products, information systems, and services related to nursing care services

(Note) It is the name of an internal organization that manages the Digital Workplace Business and the Professional Print Business.

(b) Information by reportable segment

Information by reportable segment of the Group is as follows. Segment profit refers to the operating profit of the segment.

Three months ended June 30, 2025

(Millions of yen)

	Reportable segments					Others	Adjustments (Note 2) (Note 3)	Total
	Business Technologies Business		Industry Business	Imaging Solutions Business	Total			
	Digital Workplace Business	Professional Print Business						
Revenue								
External	139,655	64,277	28,801	18,320	251,055	148	—	251,204
Intersegme nt (Note 1)	866	14	1,104	156	2,141	3,116	(5,258)	—
Total	140,522	64,291	29,906	18,476	253,196	3,265	(5,258)	251,204
Segment profit (loss)	6,742	449	4,010	1,486	12,689	(13)	(2,613)	10,062

Three months ended June 30, 2026

(Millions of yen)

	Reportable segments					Others	Adjustments (Note 2) (Note 3)	Total
	Business Technologies Business		Industry Business	Imaging Solutions Business	Total			
	Digital Workplace Business	Professional Print Business						
Revenue								
External	149,138	58,102	31,796	19,308	258,345	171	—	258,517
Intersegme nt (Note 1)	977	5	1,106	123	2,212	3,344	(5,556)	—
Total	150,115	58,107	32,903	19,432	260,558	3,515	(5,556)	258,517
Segment profit (loss)	7,750	4,026	5,260	(1,671)	15,366	152	(5,898)	9,620

(Notes)

1. Intersegment revenue is based on market prices and others.
2. Adjustments of revenue are elimination of intersegment transactions.
3. Adjustments of segment profit are elimination of intersegment transactions and corporate expenses, which consist of general and administrative expenses and basic research expenses not attributable to any of the reportable segments or "Others." They include other revenue and other expenses not attributable to any of the reportable segments.

[Cash and Cash equivalents]

Cash and cash equivalents at the end of the period in the quarterly condensed consolidated statements of cash flows are as follows:

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash and cash equivalents in the quarterly condensed consolidated statements of financial position	86,357	116,986
Cash and cash equivalents included in assets held for sale	294	—
Cash and cash equivalents in the quarterly condensed consolidated statements of cash flows	86,652	116,986

[Discontinued Operation]**(a) Outline of the discontinued operation**

The Group completed the transfer of all equity capital of Invicro, LLC to Calyx Services Inc. on April 30, 2024. In addition, on February 3, 2025, the Group completed to transfer all shares of Ambry Genetics to Tempus. As a result, the Precision Medicine Business is classified as a discontinued operation, and profit or loss from discontinued operation is presented separately from continuing operations in the quarterly consolidated statements of profit or loss.

(b) Profit or loss from discontinued operation

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Discontinued Operation		
Income (Note 1)	4,059	2,961
Expenses (Note 2)	1,088	17
Profit (loss) before tax from discontinued operation	2,971	2,943
Income tax expense	(12)	(4)
Profit (loss) from discontinued operation	2,984	2,948

(Notes)

- During the three months ended June 30, 2025, a profit of 3,124 million yen, which was recognized as a result of the realization of the partial sale and the changes in the fair value of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics is included.
During the three months ended June 30, 2026, a profit of 2,916 million yen, which was recognized as a result of the realization of the sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics, is included. The Company has now completed the sale of all Tempus shares it held.
- During the three months ended June 30, 2025, a loss of 329 million yen is included, which was recognized as a result of measuring Konica Minolta REALM Inc. at fair value less costs to sell.

(c) Profit attribution

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Owners of the Company		
Profit (loss) from continuing operations	4,314	4,832
Profit (loss) from discontinued operation	2,969	2,948
Total	7,283	7,780
Non-controlling interests		
Profit (loss) from continuing operations	307	33
Profit (loss) from discontinued operation	14	—
Total	322	33

(d) Cash flows from discontinued operation

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities	(1,800)	123
Cash flows from investing activities (Note)	16,945	15,958
Cash flows from financing activities	(266)	—
Total	14,878	16,081

(Note) During the three months ended June 30, 2025, a proceed from sale of investment securities of 16,966 million yen, which was a result of the realization of the partial sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics, is included.

During the three months ended June 30, 2026, a proceed from sale of investment securities of 15,958 million yen, which was a result of the realization of the sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics, is included.